| Secondary |
| Product Used For Unknown Indication |
17.9% |
| Rheumatoid Arthritis |
16.0% |
| Drug Use For Unknown Indication |
12.0% |
| Pain |
8.7% |
| Pyrexia |
7.5% |
| Hypertension |
4.2% |
| Nasopharyngitis |
4.1% |
| Gastritis |
4.0% |
| Herpes Zoster |
2.9% |
| Headache |
2.7% |
| Prophylaxis |
2.6% |
| Pharyngitis |
2.3% |
| Arthralgia |
2.2% |
| Back Pain |
2.0% |
| Constipation |
1.9% |
| Ill-defined Disorder |
1.9% |
| Mantle Cell Lymphoma |
1.9% |
| Epilepsy |
1.8% |
| Benign Prostatic Hyperplasia |
1.7% |
| Infection Prophylaxis |
1.7% |
|
| Renal Failure Acute |
11.8% |
| Stevens-johnson Syndrome |
10.0% |
| Liver Disorder |
5.5% |
| Toxic Epidermal Necrolysis |
5.5% |
| Tubulointerstitial Nephritis |
5.5% |
| Urticaria |
5.5% |
| Vomiting |
5.5% |
| White Blood Cell Count Increased |
5.5% |
| Hepatitis Fulminant |
4.5% |
| Large Intestinal Ulcer |
4.5% |
| Rash |
4.5% |
| Renal Impairment |
4.5% |
| Alanine Aminotransferase Increased |
3.6% |
| Arthritis Bacterial |
3.6% |
| Diarrhoea |
3.6% |
| Hepatic Function Abnormal |
3.6% |
| Pyrexia |
3.6% |
| Urine Output Decreased |
3.6% |
| Anaemia |
2.7% |
| Blister |
2.7% |
|
| Concomitant |
| Rheumatoid Arthritis |
21.4% |
| Product Used For Unknown Indication |
18.4% |
| Prophylaxis |
9.9% |
| Drug Use For Unknown Indication |
6.1% |
| Hypertension |
5.1% |
| Constipation |
4.0% |
| Insomnia |
3.6% |
| Chronic Hepatitis C |
3.4% |
| Aplastic Anaemia |
3.0% |
| Cancer Pain |
2.9% |
| Premedication |
2.8% |
| Hiv Infection |
2.7% |
| Infection Prophylaxis |
2.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.6% |
| Pain |
2.3% |
| Gastritis Prophylaxis |
2.0% |
| Osteoporosis |
2.0% |
| Fabry's Disease |
1.8% |
| Depression |
1.7% |
| Breast Cancer |
1.5% |
|
| Subarachnoid Haemorrhage |
12.8% |
| Pneumonia |
10.9% |
| White Blood Cell Count Decreased |
10.3% |
| Pyrexia |
9.8% |
| Vomiting |
5.9% |
| Interstitial Lung Disease |
5.5% |
| Herpes Zoster |
4.6% |
| Sepsis |
4.1% |
| Stomatitis |
3.9% |
| Rash |
3.6% |
| Speech Disorder |
3.4% |
| Cerebral Haemorrhage |
3.2% |
| Liver Disorder |
3.0% |
| Peritonitis |
3.0% |
| Staphylococcal Infection |
3.0% |
| Cerebral Infarction |
2.7% |
| Vocal Cord Paralysis |
2.7% |
| White Blood Cell Count Increased |
2.7% |
| Ileitis |
2.5% |
| Malaise |
2.5% |
|
| Interacting |
| Drug Use For Unknown Indication |
38.5% |
| Upper Respiratory Tract Inflammation |
23.1% |
| Diabetes Mellitus |
15.4% |
| Analgesic Therapy |
7.7% |
| Endocarditis Prophylaxis |
7.7% |
| Gonalgia |
7.7% |
|
| Hypoglycaemia |
33.3% |
| Post Procedural Haemorrhage |
33.3% |
| Toxicity To Various Agents |
33.3% |
|
